Biocon:EnhancingGlobalHealthcare

FactSheet

About: Vision

Biocon Limited is 's largest and fully-integrated, innovation-led To enhance company. As an emerging global biopharmaceutical enterprise, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative global products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a healthcare range of Novel Biologics, , differentiated Small Molecules and affordable through Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are

® ® ™ INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb- innovative and EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high affordable potential oral prandial insulin. biopharma A Credible Biopharma Enterprise: products for • 1200+ patent application filed globally* patients, • 984 Patents granted*

• 448 Trademark Registrations* partners and

• 7 Biologics including 2 Novels and 5 Biosimilars taken from Lab to Market healthcare

• Key Brands : Insugen®, BASALOG®, ALZUMAbTM, BIOMAb EGFR®, CANMAbTM, ERYPROTM, BLISTO®, STATIX®, TACROGRAFTM, CytosorbTM, CimivirTM systems

• ~120 countries where our products are available across the

• 25+ cGMP approvals from international regulatory agencies* globe. • Key regulatory approvals from US, EU, Japan, France, Brazil, Mexico, Turkey, GCC etc.

R&D Revenue Spending Employees `35,699* `4,270* 8,000+* million million

*As of 31 March 2016 Industry Leadership:

• India's first publicly listed biotech company. Manufacturing • Developed and launched India's first Novel Biologic, BIOMAb-EGFR®, for head and neck cancer. Locations • Developed novel first-in-class anti-CD6 humanized monoclonal antibody, Itolizumab, which has been launched as ALZUMAb™ for the treatment of chronic plaque psoriasis in India. Malaysia • CANMAb™, launched in India in 2014, is the first follow-on biologic Trastuzumab to be approved anywhere in the world. Hyderabad • Biocon's Insulin Glargine, a long-acting insulin analog, is the first from India to be approved and launched in Japan. Visakhapatnam • Biocon is the largest Asian insulins player and the fourth largest producer of insulins in the world. • Biocon is the world's largest statins manufacturer; its drug substance is being used to produce 'one in every three' statin pills globally. • Biocon is developing Insulin Tregopil, a novel 'first-in-class' oral prandial insulin. • Among the highest R&D spenders in India. • Ranked among Top 10 Global Biotech Employers by prestigious US-based Science magazine.

Growth Verticals: Aligned with Shifting Paradigms

Novel Biologics & Biosimilars (rh-insulin, Insulin Analogs, Monoclonal Antibodies & Recombinant Proteins) Biologics

GROWTH Branded Formulations Small Molecules VERTICALS Finished Dosage Business in Differentiated APIs & India & Overseas Generic Formulations

Research Services Syngene (Molecular Biology, Biologics, Synthetic Chemistry, Bioinformatics & Clinical Research)

For more information contact: Seema Ahuja VP & Global Head of Communications T: +91-80-2808-2222 Email: [email protected]

Issued by Corporate Communications | Email: [email protected] | www.biocon.com